Cover Image
Market Research Report

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

Published by Global Markets Direct Product code 410982
Published Content info 56 Pages
Immediate Delivery Available
Price
Back to Top
Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017
Published: June 27, 2017 Content info: 56 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERSCoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9449IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Middle East Respiratory Syndrome (MERS) - Overview
    • Middle East Respiratory Syndrome (MERS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
    • Atriva Therapeutics GmbH
    • Autoimmune Technologies LLC
    • Fab'entech SA
    • Gilead Sciences Inc
    • Humabs BioMed SA
    • Inovio Pharmaceuticals Inc
    • Nanotherapeutics Inc
    • NanoViricides Inc
    • Novavax Inc
    • Phelix Therapeutics LLC
    • Planet Biotechnology Inc
    • Regeneron Pharmaceuticals Inc
    • Romark Laboratories LC
  • Middle East Respiratory Syndrome (MERS) - Drug Profiles
    • 3B-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATR-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNSP-333S1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSW-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBR-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-2101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCA-60 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitazoxanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3048 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAB-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Middle East Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Middle East Respiratory Syndrome (MERS) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300
      • Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
      • Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment
      • Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Fab'entech SA, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Nanotherapeutics Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Planet Biotechnology Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1 2017

List of Figures

  • Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top